Today: 21 May 2026
Browse Category

NASDAQ:CMCT 12 November 2025 - 9 December 2025

CMCT Stock: How Creative Media & Community Trust’s Lending Sale, Q3 2025 Results and New LA Project Shape the 2026 Outlook

CMCT Stock: How Creative Media & Community Trust’s Lending Sale, Q3 2025 Results and New LA Project Shape the 2026 Outlook

CMCT closed at $3.49 on December 2, 2025, down 6.9% for the day, with a market cap between $2–4 million. The stock has swung between $4 and $80 over the past year, following a 1-for-25 reverse split and major volatility. Short interest stands at about 48% of free float. Recent events include a deal to sell its SBA lending unit and the opening of a 36-unit apartment building in Los Angeles.
3 December 2025
CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

Creative Media & Community Trust Corporation agreed to sell its lending division, First Western SBLC/PMC Commercial Trust, to Peachtree Group affiliate PG FR Holding for about $44 million. The deal is expected to net CMCT $31 million after debt and costs, pending SBA approval. CMCT shares surged 66% intraday following the announcement. CFO Barry N. Berlin will resign at closing and is expected to join the buyer.
12 November 2025
·
CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

Creative Media & Community Trust Corporation agreed to sell its lending division, First Western SBLC, Inc., to a Peachtree Group affiliate for about $44 million, pending SBA approval. CMCT expects roughly $31 million in net cash after debt and fees. CFO Barry Berlin will resign at closing, with Brandon Hill set to take over. Shares jumped over 70% intraday following the announcement.
12 November 2025
···

Stock Market Today

  • Asia Stocks Rally as Trump Signals Progress on U.S.-Iran Peace Deal
    May 20, 2026, 11:38 PM EDT. Asia's stock markets opened higher following President Trump's signals of nearing the final stages of a U.S.-Iran peace deal, sparking a relief rally across equities. The potential resolution eased geopolitical tensions, boosting investor confidence in the region. According to senior market analyst Kelvin Wong based in Singapore, this development is pivotal as it reduces uncertainty in markets, supporting a positive outlook for stock and foreign exchange sectors. The rally exemplifies how geopolitical developments can swiftly influence financial markets, underlining the importance of global macro analysis in identifying key market reversal points.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop